TPB · Investment summary · as of 4 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
The evidence needed to judge business quality is not established, so the underwriting supports no position.
At $80.40, TPB requires a 20% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 25%.
Declared MARGIN on two measured grounds. (1) The margin axis is the tighter constraint: growth-axis slack is +5.58pp of CAGR, margin-axis slack is +3.27pp against the ACTUAL TTM margin - and consensus already models FY2027 at 14.9%, only 0.58pp above the 14.32% the price requires.
The conditions that would settle the disagreement are dated cumulative over 5 years (~3.9% p.a.).
The value rests on an exit multiple of 11.4x, a terminal operating margin of 18% and a 7.9% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Declared MARGIN on two measured grounds. |
| What do we forecast? | Revenue growth of 25% demonstrated; a terminal operating margin of 18%; an exit multiple of 11.4x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is +3.3 percentage points. |
| What is it worth? | Twelve-month target $79.20, -1% from the struck price. Scenario-weighted expected return net of costs -1.5%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Date not announced — no dated event that would resolve the disagreement is on file
Not determined — no permanent-loss case with a named cause is on file; a bear valuation is not an impairment case
Estimated probability 18%, against the 11% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Trim when the traded NTM EV/EBIT exceeds 27.5x (the 1-year average, at which the required CAGR falls to 0.37% and the entire five-year path is discounted into the price) OR when the price reaches $121.63 (the 1-year-median-multiple target), whichever comes first. On approach to the $79.20 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 8% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Not determined | What is the realistic permanent-loss case? Not established on the evidence on file. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +3.3 percentage points more growth than the price requires. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $70.75, which forces an immediate review.